Shannon Tyler, MD
Infectious Disease · Mobile, ALNPI 1205883154
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Gilead accounts for 62.1% of it on its own, with 18 other manufacturers making up the rest.
Across 521 payments — averaging $45.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$15K
- Viiv Healthcare Company$4K
- Theratechnologies Inc.$2K
- Merck$1K
- Johnson & Johnson$534
- Melinta Therapeutics, LLC$472
- plus $1K from 13 others
What the payments were for
- Consulting fees$11,21547%
- Speaking & faculty fees$1,4756%
- Travel & lodging$1,0584%
- Food & beverage$9,49940%
- Education$5042%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 166 | $14,745 |
| Viiv Healthcare Company | 182 | $3,615 |
| Theratechnologies Inc. | 12 | $1,971 |
| Merck | 60 | $1,163 |
| Johnson & Johnson(2 entities) | 36 | $534 |
| Melinta Therapeutics, LLC | 21 | $472 |
| Astellas Pharma US Inc | 12 | $398 |
| Janssen Products, LP | 3 | $297 |
| AbbVie(2 entities) | 9 | $165 |
| Shionogi Inc | 5 | $100 |
| Vyera Pharmaceuticals, LLC | 4 | $63 |
| Insmed, Inc. | 2 | $46 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $40 |
| Regeneron | 1 | $34 |
| Napo Pharmaceuticals Inc | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Invivyd Inc | 1 | $21 |
| Medtronic | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,751 in reported general payments places this provider in the 85th percentile of 104 infectious disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 494 | $2,058,698 |
| TivicayDolutegravir Sodium | 294 | $712,747 |
| DovatoDolutegravir Sodium/Lamivudine | 203 | $639,504 |
| RukobiaFostemsavir Tromethamine | 45 | $457,573 |
| DescovyEmtricitabine/Tenofov Alafenam | 184 | $424,859 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 54 | $273,991 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 63 | $236,591 |
| PrezcobixDarunavir/Cobicistat | 75 | $189,261 |
| PifeltroDoravirine | 93 | $170,033 |
| CabenuvaCabotegravir/Rilpivirine | 16 | $107,136 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 22 | $87,645 |
| IsentressRaltegravir Potassium | 28 | $58,721 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $43,276 |
| Maraviroc | 21 | $30,322 |
| Lamivudine-ZidovudineLamivudine/Zidovudine | 25 | $7,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $14,745 | $2,571,202700 claims |
| Viiv Healthcare CompanyTivicay, Dovato, Rukobia, Triumeq, Cabenuva | $3,615 | $2,153,551621 claims |
| Janssen Products, LPSymtuza | $297 | $273,99154 claims |
| MerckPifeltro, Isentress | $1,163 | $228,755121 claims |
| Johnson & JohnsonPrezcobix | $534 | $189,26175 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 104 infectious disease providers in Alabama.
Other infectious disease in Mobile
- Dahlene FuscoMobile$21K
- Eduardo CalderonMobile$19K
- Amber BokhariMobile$7K
- John Vande WaaMobile$5K
- Patrick NolanMobile$5K
- Edward HyndmanMobile$4K
- Steven AlsipMobile$2K
- C BodetMobile$2K
- Jenifer YehMobile$923
- Timothy IliffMobile$876
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.